Last reviewed · How we verify
Slo-Niacin, atorvastatin
Slo-Niacin (niacin) reduces triglycerides and raises HDL cholesterol, while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and overall cardiovascular risk.
Slo-Niacin (niacin) reduces triglycerides and raises HDL cholesterol, while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol and overall cardiovascular risk. Used for Dyslipidemia and hypercholesterolemia, Cardiovascular disease prevention.
At a glance
| Generic name | Slo-Niacin, atorvastatin |
|---|---|
| Also known as | Lipitor (R) (Atorvastatin), Slo-Niacin (R) (time-release niacin |
| Sponsor | University of Washington |
| Drug class | Niacin derivative and HMG-CoA reductase inhibitor (statin combination) |
| Target | Nicotinic acid receptor (GPR109A) and HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Niacin is a B vitamin that decreases hepatic VLDL production and increases HDL cholesterol through nicotinic acid receptor signaling. Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Together, this combination addresses multiple lipid abnormalities to reduce atherosclerotic cardiovascular disease risk.
Approved indications
- Dyslipidemia and hypercholesterolemia
- Cardiovascular disease prevention
Common side effects
- Flushing
- Pruritus
- Nausea
- Myalgia
- Elevated liver enzymes
- Hyperglycemia
Key clinical trials
- Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE3)
- Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication (PHASE4)
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (PHASE3)
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (PHASE3)
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (PHASE3)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia (PHASE3)
- Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Slo-Niacin, atorvastatin CI brief — competitive landscape report
- Slo-Niacin, atorvastatin updates RSS · CI watch RSS
- University of Washington portfolio CI